discovernet program

Excited to share that we are part of three multidisciplinary collaborative research programs to push the boundaries of next-generation immunotherapy

From unlocking durable immune responses in rare cancers, to exploring the hidden potential of the dark genome, and advancing RNA-based therapeutics - these initiatives reflect the power of cross-sector collaboration in Europe.

  • dIscOverNET (Q1 2027 - Q4 2030) - Driving breakthroughs in neuroendocrine tumors by tackling tumor microenvironment and resistance mechanisms.
  • ORFeus - Expanding the frontier of non-canonical proteins and microproteins — opening entirely new target spaces in cancer immunotherapy.
  • saRplix (Q4 2025 - Q3 2029) - Bringing microfluidics and RNA innovation together to enable scalable, injection-ready personalized vaccines.

Across all three projects, we contribute our expertise in novel target discovery and next-generation immunotherapy design, alongside leading academic, clinical, and industry partners.

Together, these programs represent €12M+ in funding, 40+ partners, and a shared ambition to redefine how we discover and develop cancer therapies.

discovernet
1 / 3